Cannabinoid Modulation of Recovery from HIV-Associated Synaptic Toxicity
大麻素对 HIV 相关突触毒性恢复的调节
基本信息
- 批准号:7385609
- 负责人:
- 金额:$ 18.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-13 至 2009-09-12
- 项目状态:已结题
- 来源:
- 关键词:AIDS Dementia ComplexAcquired Immunodeficiency SyndromeAgonistAnti-Retroviral AgentsAntiemeticsAppetite StimulantsBackBiological AssayCNR1 geneCannabinoidsCell DeathCentral Nervous System InfectionsCessation of lifeChromosome PairingConditionDLG4 geneDetectionDevelopmentDiseaseEndocannabinoidsExcisionExcitatory NeurotoxinsExposure toFoundationsFutureGlutamatesHIVHIV tat ProteinHIV-1Hippocampus (Brain)HourImageImpaired cognitionIn VitroLasersMaintenanceMicrogliaMorphologyNeurocognitiveNeurodegenerative DisordersNeuronsNeurophysiology - biologic functionNeurotoxinsNumbersPatientsPharmaceutical PreparationsProteinsRattusReceptor ActivationRecoveryRoleScaffolding ProteinScanningSynapsesSynaptic TransmissionTestingTetrahydrocannabinolTimeToxic effectToxinVirus Sheddingbasebrain cellcannabinoid receptordensitydrug of abuseenhanced green fluorescent proteinexcitotoxicityimprovedmacrophagemulticatalytic endopeptidase complexneuron lossneurotoxicneurotoxicityneurotransmissionpostsynapticreceptorresearch studytat Protein
项目摘要
DESCRIPTION (provided by applicant): Changes in dendritic morphology such as dendritic pruning precede neuronal cell death in many neurodegenerative disorders, including HIV-1 associated dementia (HAD). The loss of synaptic connections associated with dendritic degeneration correlates with cognitive decline in these disorders. Antiretroviral treatment initially improves neurocognitive function in HAD patients. Preliminary studies quantified intact postsynaptic densities (PSDs) in rat hippocampal neurons grown in primary culture by imaging clusters of the scaffolding protein PSD95 fused to enhanced green fluorescent protein (PSD95-EGFP). This unique imaging based assay enables the number of synaptic connections between the same hippocampal neurons to be recorded over time. HIV-1 proteins and excitotoxins caused significant loss of PSD95-EGFP puncta at concentrations that failed to produce overt neuronal death. PSD loss preceded cell death and was reversible. Synaptic activity is required for the development and stability of synapses and cannabinoids, drugs given to AIDS patients clinically and widely used illicitly, modulate excitatory neurotransmission and excitotoxicity. The hypothesis that cannabinoid agonists slow recovery of synapses following exposure to excitotoxins or HIV proteins will be tested. A detailed time course for recovery of PSD95-EGFP puncta following removal of toxin will be recorded and the effects of pharmacological block of excitatory synaptic transmission determined. A cannabinoid receptor full agonist, the partial agonist ?9-tetrahydrocannabinol and a receptor antagonist will be used to evaluate the role of varying degrees of CB1 receptor activation and endocannabinoid tone on recovery of PSDs. Cannabinoid receptor agonists are predicted to impair the ability of neurons to integrate back into the synaptic network following neurotoxic insult. If cannabinoids inhibit synaptic recovery, these studies would caution against recreational use of cannabinoids or their use as antiemetics and appetite stimulants in patients with HAD. This project may provide a foundation for future studies to evaluate the effects of drugs of abuse on the recovery of neural function following HIV-1 infection of the central nervous system.
描述(由申请人提供):在许多神经退行性疾病(包括HIV-1相关痴呆(HAD))中,树突形态学变化(如树突修剪)先于神经元细胞死亡。与树突变性相关的突触连接的丧失与这些疾病中的认知下降相关。抗逆转录病毒治疗最初可改善HAD患者的神经认知功能。初步研究通过成像融合增强型绿色荧光蛋白(PSD 95-EGFP)的支架蛋白PSD 95簇来量化在原代培养中生长的大鼠海马神经元中的完整突触后密度(PSD)。这种独特的基于成像的测定能够随着时间的推移记录相同海马神经元之间的突触连接的数量。HIV-1蛋白和兴奋性毒素在不能产生明显神经元死亡的浓度下引起PSD 95-EGFP斑点的显著损失。PSD损失先于细胞死亡,并且是可逆的。突触活性是突触发育和稳定所必需的,大麻素类药物在临床上广泛应用于艾滋病患者,调节兴奋性神经传递和兴奋性毒性。将测试大麻素激动剂在暴露于兴奋性毒素或HIV蛋白后减缓突触恢复的假设。将记录去除毒素后PSD 95-EGFP斑点恢复的详细时间过程,并确定兴奋性突触传递的药理学阻断的影响。大麻素受体完全激动剂,部分激动剂?9-四氢大麻酚和受体拮抗剂将用于评估不同程度的CB 1受体活化和内源性大麻素紧张度对PSD恢复的作用。预计大麻素受体激动剂会损害神经元在神经毒性损伤后整合回突触网络的能力。如果大麻素抑制突触恢复,这些研究将警告大麻素的娱乐性使用或其作为HAD患者的止吐剂和食欲刺激剂。该项目可能为未来的研究提供基础,以评估滥用药物对中枢神经系统HIV-1感染后神经功能恢复的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stanley A Thayer其他文献
Stanley A Thayer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stanley A Thayer', 18)}}的其他基金
Antiretroviral Drug-Induced Changes in Synapses between Human iPSC-Derived Cortical Neurons to Assess Risk and Mechanisms of Neuropsychiatric Adverse Effects
抗逆转录病毒药物引起的人 iPSC 衍生皮质神经元之间突触的变化可评估神经精神不良反应的风险和机制
- 批准号:
10023282 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
Antiretroviral Drug-Induced Changes in Synapses between Human iPSC-Derived Cortical Neurons to Assess Risk and Mechanisms of Neuropsychiatric Adverse Effects
抗逆转录病毒药物引起的人 iPSC 衍生皮质神经元之间突触的变化可评估神经精神不良反应的风险和机制
- 批准号:
9921599 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
Synapse loss induced by HIV-1 proteins in the presence of ART and drugs of abuse
在 ART 和滥用药物的情况下,HIV-1 蛋白引起的突触损失
- 批准号:
9408151 - 财政年份:2017
- 资助金额:
$ 18.69万 - 项目类别:
Scalable assay for drugs to reverse synapse loss during HIV-1 neurotoxicity
逆转 HIV-1 神经毒性期间突触损失的药物的可扩展测定
- 批准号:
8792421 - 财政年份:2014
- 资助金额:
$ 18.69万 - 项目类别:
Scalable assay for drugs to reverse synapse loss during HIV-1 neurotoxicity
逆转 HIV-1 神经毒性期间突触损失的药物的可扩展测定
- 批准号:
9228409 - 财政年份:2014
- 资助金额:
$ 18.69万 - 项目类别:
Scalable assay for drugs to reverse synapse loss during HIV-1 neurotoxicity
逆转 HIV-1 神经毒性期间突触损失的药物的可扩展测定
- 批准号:
8678350 - 财政年份:2014
- 资助金额:
$ 18.69万 - 项目类别:
Pharmacological modulation of synapses and cognition during HIV-1 neurotoxicity
HIV-1神经毒性过程中突触和认知的药理学调节
- 批准号:
8536498 - 财政年份:2013
- 资助金额:
$ 18.69万 - 项目类别:
Pharmacological modulation of synapses and cognition during HIV-1 neurotoxicity
HIV-1神经毒性过程中突触和认知的药理学调节
- 批准号:
8650820 - 财政年份:2013
- 资助金额:
$ 18.69万 - 项目类别:
Effects of Chronic Opiates on Endocannabinoid Signaling at Excitatory Synapses
慢性阿片类药物对兴奋性突触内源性大麻素信号传导的影响
- 批准号:
7612861 - 财政年份:2008
- 资助金额:
$ 18.69万 - 项目类别:
Cannabinoid Modulation of Recovery from HIV-Associated Synaptic Toxicity
大麻素对 HIV 相关突触毒性恢复的调节
- 批准号:
7495016 - 财政年份:2007
- 资助金额:
$ 18.69万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 18.69万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 18.69万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 18.69万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 18.69万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 18.69万 - 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
- 批准号:
03660315 - 财政年份:1991
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 18.69万 - 项目类别:














{{item.name}}会员




